PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
ID: 355265Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355265

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-24-245.html
Timeline
    Description

    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) grant applications. This funding opportunity invites eligible U.S. small businesses to propose innovative projects that demonstrate significant commercialization potential, specifically excluding clinical trials. The grants aim to support research and development aligned with the missions of the NIH, CDC, and FDA, with funding amounts typically reaching up to $306,872 for Phase I and $2,045,816 for Phase II awards. Interested applicants must submit their proposals by April 5, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PA-24-245.html for further details.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-24-245-Full-Announcement.html
    Please provide the text you would like summarized.
    PA-24-245.html
    The Department of Health and Human Services has released a Notice of Funding Opportunity (NOFO) inviting U.S. small businesses to apply for Small Business Innovation Research (SBIR) grants from the NIH, CDC, and FDA. This opportunity allows companies to propose projects that have significant commercialization potential without involving clinical trials. The announcement details the participation of various NIH components and CDC centers, with funding available under several SBIR phases—Phase I, Phase II, Fast-Track, and Direct to Phase II. Eligible small businesses must comply with specified criteria, including being U.S.-based and primarily owned by U.S. citizens. The NOFO outlines application submission requirements, including the necessity for various registrations and adherence to strict application guidelines. Funding amounts generally do not exceed $306,872 for Phase I and $2,045,816 for Phase II awards, with project periods not exceeding 6 months and 2 years, respectively. Applicants are encouraged to develop a strong commercialization plan, reflecting the potential to bring innovative solutions to market, thereby advancing the health technologies aligned with the missions of the NIH, CDC, and FDA.
    Similar Opportunities
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) to support pre-clinical research aimed at bridging funding gaps that impede the commercialization of medical biotechnology products. This funding opportunity specifically targets previously funded SBIR or STTR Phase II projects, with the objective of advancing products or technologies that require federal regulatory approval, while fostering partnerships between small businesses and external investors to enhance commercialization prospects. Applicants are encouraged to secure independent third-party funding that equals or exceeds one-third of the requested NINDS funds, and must include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in the research environment. The application deadline is April 5, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-222.html.
    NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering NINDS Renewal Awards of Small Business Innovation Research (SBIR) Phase II Grants (Phase IIB) to support clinical trials and clinical research projects focused on neurological disorders. This funding opportunity encourages small business concerns (SBCs) to seek additional funding for projects previously funded by NIH SBIR and STTR Phase II awards, with an emphasis on facilitating the transition of these projects to commercialization through partnerships with third-party investors. The initiative aims to address the "Valley of Death" funding gap in medical biotechnology, particularly for products related to the mission of the National Institute of Neurological Disorders and Stroke (NINDS). Interested applicants must submit a Commercialization Plan and a Plan for Enhancing Diverse Perspectives (PEDP), with the application opening on August 5, 2024, and a closing date of April 5, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) to support early-career scientists transitioning into entrepreneurial roles within small businesses. This funding opportunity aims to facilitate the career development of investigators by providing entrepreneurial training, mentorship, and support for research and development projects that align with NIH's mission to improve health. Eligible small business concerns (SBCs) can apply for Phase I and Fast-Track grants, with funding amounts typically reaching $306,872 for Phase I and $2,045,816 for Phase II awards. Applications will be accepted starting August 5, 2024, with a closing date of April 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-134.html.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities," aimed at supporting U.S. small businesses in developing innovative technologies, products, or services that address health disparities among minority populations. Eligible applicants are encouraged to propose solutions that enhance healthcare delivery, promote health-seeking behaviors, and overcome barriers in minority health, with funding available through the Small Business Innovation Research (SBIR) program for both Phase I and II grants. This initiative underscores the government's commitment to advancing health equity and leveraging small business innovation to tackle significant healthcare challenges faced by underserved communities. Applications are due by December 10, 2026, and interested parties can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the Small Business Innovation Research (SBIR) Phase IIB Bridge Awards aimed at accelerating the commercialization of technologies related to heart, lung, blood, and sleep disorders. This initiative seeks to support small businesses in advancing promising biomedical projects that have previously received SBIR or STTR Phase II funding, addressing the critical funding gap that often hinders the transition to commercialization and regulatory approval. The program is designed to foster partnerships between SBIR Phase II awardees and third-party investors, with a total estimated funding of $52.5 million and individual awards capped at $3.5 million. Interested applicants should prepare to submit proposals by February 25, 2025, with the anticipated award date set for December 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the NHLBI SBIR Phase IIB Small Market Awards aimed at accelerating the commercialization of technologies for heart, lung, blood, and sleep disorders. This funding opportunity is designed to support small businesses in advancing promising biomedical projects that have previously received SBIR or STTR Phase II funding, specifically targeting products that address rare diseases or pediatric populations. With an estimated total program funding of $21 million and an award ceiling of $3.5 million, the anticipated application due date is February 25, 2025, with awards expected to be made by December 1, 2025. Interested applicants are encouraged to prepare their proposals in advance to meet the requirements integral to this initiative.
    FY 2025 NIST Small Business Innovation Research Program Phase II
    National Institute of Standards and Technology
    The National Institute of Standards and Technology (NIST) is inviting applications for the FY 2025 Small Business Innovation Research (SBIR) Program Phase II, specifically targeting previous Phase I award recipients from FY 2024. This opportunity aims to support the development of market-ready products or services, with a focus on enhancing innovation in federally funded research and development, while also addressing federal R&D needs through small businesses. NIST anticipates funding approximately five awards, each up to $400,000 over a 24-month project period, with applications due by June 14, 2025, submitted via Grants.gov. For further inquiries, applicants can contact Misty Roosa at Grants@nist.gov.